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Abstract
During T cell development, multipotent progenitors relinquish competence for other fates and 
commit to the T cell lineage by turning on the transcription factor Bcl11b. To clarify lineage 
commitment mechanisms, we followed developing T cells at single-cell level using Bcl11b knock-
in fluorescent reporter mice. Notch signaling and Notch-activated transcription factors collaborate 
to activate Bcl11b expression, irrespective of Notch-dependent proliferation. These inputs work 
via three distinct, asynchronous mechanisms: an early locus poising function dependent on TCF-1 
and GATA-3; a stochastic permissivity function dependent on Notch signaling; and a separate 
amplitude-control function dependent on Runx1, a factor already present in multipotent 
progenitors. Despite all being necessary for Bcl11b activation, these inputs act in a stage specific 
manner, providing a multi-tiered mechanism for developmental gene regulation.
As immune progenitors develop into T cells, they progressively relinquish access to 
alternative fates and eventually commit to becoming a T cell1,2. The final executor of this 
commitment transition is the Bcl11b gene, whose activation is a dramatic lineage-specific 
landmark in early T cell development. While Bcl11b has many roles in peripheral T cells3,4, 
where it is expressed almost universally, its initial activation is essential for establishing T 
cell identity during development5. Deletion of Bcl11b in progenitors blocks T cell 
commitment6,7, and also impairs T cell receptor re-arrangements8 and expansion of β-chain 
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expressing pre-T cells9. Later stage deletion can cause mature T cells to become NK-like 
cells10.
Bcl11b is activated late in the course of initial T cell specification. Upon stimulation by 
Notch-Delta signals in the thymus, progenitors first transition from an early T progenitor 
(ETP) stage, identified as c-Kit+ CD4 and CD8 double-negative (DN)1, to DN2a stage, 
where Bcl11b expression is first detected at the population level. DN2a progenitors then 
transition to DN2b stage, where they further increase expression of Bcl11b and lose 
potential to generate NK or dendritic cells11,12. The process of Bcl11b activation and lineage 
commitment from the earliest thymus-settling post-natal progenitors spans about ten days 
and cell cycles13, allowing cells to expand substantially before commitment is complete.
Bcl11b activation and T-lineage commitment depend on Notch signaling, and on an 
ensemble of transcription factors that includes Runx1, TCF-1 (encoded by Tcf7), and 
GATA-314–17. GATA-3 and TCF-1 are activated by Notch signaling. Runx1, already 
expressed in hematopoietic stem cells, is also upregulated by Notch15,18–20. These factors 
may all bind the Bcl11b locus concurrently to coordinate its activation, following well-
established precedents of combinatorial gene regulation21,22. In this view, the timing of 
Bcl11b activation would be controlled by slow accumulation of one or more upstream 
factors, which would need to reach a quorum on the gene locus to cause induction. 
Alternatively, these factors may collaborate in an asynchronous manner to control Bcl11b 
expression. Work from several systems has shown that some transcription factors act as 
`pioneers’, and may physically open chromatin around genes to enable subsequent binding 
of other factors23,24. Thus, Bcl11b activation and T lineage commitment could involve the 
temporally separated action of transcription factors, with some acting early to control 
activation, and others acting later to maintain expression.
Distinguishing between these models requires isolating cells in distinct gene expression 
states, and comparing their developmental plasticity. Population-level gene expression 
measurements, which average over distinct cell states and temporal stages, are not definitive 
for this. Therefore, to pinpoint the mechanisms of Bcl11b activation and T lineage 
commitment, we generated a knock-in fluorescent reporter in the Bcl11b locus, and followed 
Bcl11b activation dynamics at single-cell level using in vitro developmental assays together 
with flow cytometry and timelapse live imaging. We show that Bcl11b activation coincides 
with commitment at the single-cell level. To activate this locus, multiple transcription factors 
play precisely staged, often transient roles. The factors controlling Bcl11b expression 
amplitude differ from those that license the locus for expression competence, a regulatory 
strategy that frees the latter factors to play subsequent roles in mature T cell functional 
specialization.
Results
Bcl11b-YFP reporter recapitulates Bcl11b expression in T cells
GATA-3, TCF-1, Runx1, and Notch bind to cis-regulatory elements on the Bcl11b 
locus10,15,25,26 (Supplementary Fig. 1), and all show evidence for functional roles in Bcl11b 
expression14,16,17,27,28, but how they collaborate to control Bcl11b activation is not 
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understood. To analyze how Bcl11b activation and T cell lineage commitment work at 
single-cell level, we generated a knock-in fluorescent reporter mouse strain for Bcl11b 
expression. Using standard gene targeting, we inserted a neomycin-resistant (neo) internal 
ribosome entry site (IRES)-mCitrine (YFP) cassette into the 3’-untranslated region (UTR) of 
Bcl11b in mouse embryonic stem (ES) cells (Fig. 1a, Supplementary Fig. 2a). We then 
injected correctly targeted ES cells into blastocyst-stage embryos to generate Bcl11b+/YFP 
mice. This knock-in reporter recapitulated the dynamic regulation of Bcl11b in adult T cell 
progenitors. Bcl11b was silent in c-Kithi DN1 thymocytes (ETPs), and began to be expressed 
in DN2a thymocytes (Fig. 1a, top), as previously observed11,25,29. DN2a progenitors 
comprised two distinct populations, one where Bcl11b-YFP expression was not yet 
detectable, and another showing clear expression (Fig. 1a), suggesting that Bcl11b activation 
occurs after transition to the DN2a stage. Bcl11b-YFP expression increased during DN2b 
and DN3 stages, i.e. to TCRβ rearrangement, and was stably maintained in all subsequent 
stages and major effector T cell subsets, but not detected in B and NK cells (Fig. 1b). 
Bcl11bYFP/YFP T cells had approximately two-fold higher YFP expression than Bcl11bYFP/+ 
cells, for all subsets analyzed (Fig. 1ab). Together with the unimodal YFP expression in 
Bcl11bYFP/+ T cells beyond DN2a stage, this finding indicated that both Bcl11b alleles were 
activated in the large majority of T cells. Mice with the neo-containing Bcl11b-YFP knock-
in allele were used in all experiments shown here, but importantly, neo cassette excision 
from the Bcl11b-YFP locus did not affect its expression pattern (Supplementary Figure 3).
Bcl11b turns on after DN2a stage entry
Previous analysis of Bcl11b expression has indicated that ETPs first differentiate into CD25+ 
DN2a thymocytes, then turn on Bcl11b expression, and finally down-regulate CD44 and c-
Kit to enter the DN2b and DN3 stages. To directly verify this developmental sequence, we 
sorted ETP, Bcl11b-YFP−DN2a and Bcl11b-YFP+DN2a and (uniformly) Bcl11b-
YFP+DN2b thymocytes, and analyzed their developmental progression on OP9-DL1 stromal 
cell monolayers, an in vitro system that recapitulates all early stages of T cell 
development30. After three days, ETPs activated Bcl11b, but only after becoming CD25+ 
(Fig. 1c). The majority of Bcl11b-YFP− DN2a cells turned on Bcl11b and a subset of those 
down-regulated expression of CD44, indicating a transition to the DN2b and DN3 stages 
(Fig. 1c). Thus, Bcl11b activation is a discrete regulatory event that occurs after transition 
into the DN2a stage.
Bcl11b activation coincides with T lineage commitment
Transition of developing thymocytes from DN2a to DN2b stages coincides with loss of 
alternate lineage potential and commitment to the T lineage11. Loss of alternative potential 
could occur upon Bcl11b activation in DN2a thymocytes or only after transition of Bcl11b+ 
DN2a cells to the DN2b stage. To distinguish between these possibilities we isolated 
(Bcl11b-YFP−) ETP, Bcl11b-YFP− DN2a, Bcl11b-YFP+ DN2a and (Bcl11b-YFP+) DN2b 
progenitors from the thymi of wild-type mice, then compared their NK cell and DC 
potentials by culturing them on OP9 stromal cells that do not stimulate Notch-Delta 
signaling (Fig. 2a; see Methods for stromal cell nomenclature). When 300 sorted cells of 
each subset were cultured in these conditions, Bcl11b-YFP− ETP and Bcl11b-YFP− DN2a 
thymocytes maintained the potential to differentiate into NK cells and DCs, consistent with 
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previous observations, while NK and DC potential dropped sharply in Bcl11b-YFP+DN2a 
cells, and was absent in DN2b thymocytes (Fig. 2a). This finding was confirmed in limiting 
dilution cell cultures (Fig. 2a, lower panels). These results indicate that Bcl11b-YFP+ DN2a 
cells are already more restricted than Bcl11b-YFP−DN2a cells in alternative developmental 
potentials.
Molecular context and signature of Bcl11b activation
To determine the genome-wide transcriptome changes that accompany the change in 
developmental potential that accompanies Bcl11b activation, we carried out RNA-seq gene 
expression analysis using culture of immature bone marrow cells on OP9-DL1 monolayers 
as a source of large numbers of semi-synchronized DN thymocytes (Fig. 2b). Cells were 
sorted after a week in culture, when the majority of cultured CD45+ cells were DN2 cells 
just beginning to turn on Bcl11b, with a minority remaining c-Kit+CD44+ CD25− ETP-like 
(henceforth called ETP)(for ex vivo and in vitro-derived population criteria, see Methods). 
Similar to thymic progenitors, bone marrow-derived progenitors showed a reduction in NK 
cell potential upon Bcl11b activation (Fig. 2c). Transcriptome analysis showed that the 
patterns of gene expression in bone marrow-derived DN2 subsets first turning on Bcl11b-
YFP fell into a smooth trajectory in principal component space, which was intermediate 
between early DN2a cells and DN2b cells (Fig. 2d). Heat maps of gene expression for the 
most dynamically changing genes overall (Fig. 2e, Supplementary Table 1) and for 
functionally important transcription factor genes (Fig. 2e, Supplementary Table 2a) are also 
shown. As DN2 cells progressed from Bcl11b-YFP− to Bcl-11b-YFP+, they increased 
expression of T cell identity genes, including T cell receptor signaling components (Cd3g, 
Cd3d, Lat) and the recombinase activating gene Rag1 (Fig. 2e, gold), while downregulating 
stem cell-, NK cell- and myeloid cell-associated genes (Fig. 2e, blue, green and black), 
consistent with their reduced lineage plasticity. Known T cell developmental regulators 
showed very limited expression changes as Bcl11b-YFP expression was turned on (Fig. 2e). 
Multiple differences were observed between ETP and Bcl11b-YFP− DN2 progenitors (Ets1, 
Tcf7, Dtx1, Bcl11a, Sfpi1, Mef2c and Lmo2, p < 0.005; Supplementary Table 2a,b), and 
between Bcl11b-YFPlo and Bcl11b-YFP+ DN2 cells (Sox13, Ets1, Lmo2, p < 0.005; 
Supplementary Table 2a,b). However, for the same probability cutoff, no significant 
expression differences among regulators could be observed between Bcl11b-YFP− and 
Bcl11b-YFPlo cells, except for Bcl11b itself (Supplementary Table 2b). Gene expression and 
lineage potential assays together thus demonstrate that Bcl11b activation in individual cells 
coincides with loss of lineage plasticity and acquisition of a committed T cell state.
Control of Bcl11b activation by Notch and IL-7 signaling
Bcl11b is expressed only in the Notch-driven T cell and innate lymphoid cell 2 programs 
(ILC2) (rev. in31), and chromatin immune precipitation evidence shows binding of Notch1 
intracellular domain and CSL to the Bcl11b locus (Supplementary Fig. 1),10,26 suggesting 
that Notch-Delta signaling may regulate Bcl11b expression directly. Bcl11b activation may 
also be triggered by removal of IL-7-IL-7R signals7. We therefore examined how Notch 
signals and IL-7 withdrawal affected Bcl11b activation in individual bone marrow-derived 
DN progenitors, sorted from OP9-DL1 pre-cultures at different stages of development. Like 
ETP thymocytes, bone marrow-derived progenitors cultured with Notch ligands and IL-7 
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turn on CD25 to enter the DN2a stage, and then turn on Bcl11b to enter a committed state 
(Fig. 3a).
Optimal Bcl11b-YFP induction from input BM-derived ETPs depended on Notch signaling 
and on minimizing IL-7 amounts in culture (Fig. 3b), consistent with previous reports7. 
ETPs activated Bcl11b-YFP much more efficiently when growing on OP9-DL1 than on 
OP9, and most efficiently on OP9-DL1 when IL-7 was removed (Fig. 3b). ETP cells 
cultured on OP9 stroma down-regulated the stem cell marker c-Kit (Fig. 3b, left), consistent 
with differentiation into an alternate lineage. However, for cells that had already activated 
Bcl11b-YFP, Notch signaling was unnecessary for maintaining Bcl11b expression (Fig. 3b). 
Bcl11b-YFP+ cells maintained similarly high Bcl11b-YFP expression after four days of 
culture on OP9 and OP9-DL1 stromal cells alike, even though CD25 expression was 
strongly downregulated in the same Bcl11b-YFP+ cells on OP9 compared to OP9-DL1 
cultures (Fig. 3b). Similarly, IL-7 dosage in the culture had little effect on maintenance of 
Bcl11b-YFP expression by Bcl11b-YFP+ cells (Fig. 3b). Between these poles, in Bcl11b-
YFP− DN2 cells IL-7 withdrawal also caused a moderate increase in Bcl11b-YFP+ 
frequency, while accelerating the down-regulation of c-Kit (Fig. 3b). However, unlike ETP 
cells, Bcl11b-YFP− DN2 cells cultured on OP9 showed a split response after four days (Fig. 
3b, middle columns). About 50% of the Bcl11b-YFP− DN2 cells on OP9 failed to up-
regulate Bcl11b-YFP, but 50% activated Bcl11b-YFP at least as robustly as on OP9-DL1 
(Fig. 3b). These results suggest that Notch signaling and IL-7 mainly affect onset, not 
maintenance of Bcl11b expression.
Bcl11b-YFP activation is independent of the cell cycle
The results could indicate that Notch signaling activates Bcl11b-YFP expression or that it 
selectively promotes proliferation of Bcl11b-YFP+ cells. To distinguish these options, we 
measured cell division rates of Bcl11b-YFP− DN2 progeny using CellTrace Violet. Bcl11b-
YFP− DN2 cells cultured on OP9-DL1 went through 8 cell cycles of cell division in 4 days 
compared to 5–6 cell cycles on OP9 in the same time interval (Fig. 4a,b). However, poised 
progenitors that turned on Bcl11b-YFP divided a similar number of times as those remaining 
Bcl11b-YFP negative, whether cultured on OP9 or OP9-DL1 (Fig. 4a). Thus, Notch 
signaling did not expand Bcl11b-expressing cells preferentially.
Still, Notch signaling effects on proliferation raised the possibility that Bcl11b activation 
could require passage through a threshold number of cell cycles, and this could bias 
detection of Bcl11b transcription in favor of Notch-signaled cells. Such a cell-cycle counting 
mechanism could be based on a need to remodel chromatin during S phase, to reposition it 
after mitosis or to dilute out pre-existing negative regulators, and could involve the Notch-
induced cell cycle driver c-Myc32. We therefore tested whether the effect of Notch signaling 
on Bcl11b-YFP activation in Bcl11b-YFP− DN2 cells was altered by over-expression of 
Myc, which accelerates proliferation, or by treatment with the cyclin-dependent kinase 
inhibitor PD0332991, which slows proliferation33. Bcl11b-YFP− DN2 cells retrovirally 
transduced with Myc proliferated as much in OP9 cultures as in OP9-DL1 cultures (Fig. 4b). 
However, Myc over-expression had little impact on Bcl11b activation compared to empty 
vector in the cells in OP9 co-culture (Fig. 4c). Conversely, PD0332991 severely blocked 
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proliferation (Fig. 4b), but did not significantly impede Bcl11b activation by Bcl11b-YFP− 
DN2 cells (Fig. 4c) compared to untreated controls. Thus, a cell cycle counting-based 
mechanism is not rate-limiting for Bcl11b induction in Bcl11b-YFP− DN2 cells. Together, 
these results suggest that Notch signaling directly enhances Bcl11b activation rate, 
independent of the cell cycle.
Notch signals enhance probabilistic rate of Bcl11b induction
To directly visualize effects of Notch on poised Bcl11b-YFP− DN2 progenitors, we sorted 
Bcl11b-YFP− DN2 cells derived from bone marrow precursors, and re-cultured them on 
OP9 and OP9-DL1 stroma with continuous live imaging. When cultured on OP9 stroma, a 
small fraction of cells turned on Bcl11b-YFP expression within the first two days of imaging 
observation (Fig. 5a,b), and this fraction increased steadily until it reached a plateau value of 
~0.4 at about 80–90 hours of culture(Fig. 5c–e). Compared to OP9 stromal cultures, OP9-
DL1 stroma doubled the fraction of cells that turned on Bcl11b-YFP expression even at <2 
days of culture (Fig. 5a,c,d, e) and accelerated first Bcl11b-YFP induction for individual cell 
lineages, as assessed by single-cell tracking (Fig. 5b). This indicates that Notch signaling 
plays a direct and immediate role in controlling Bcl11b activation. Even with continued 
Notch signaling, the fraction of cells expressing Bcl11b also appeared to reach a plateau 
value (~0.8, Fig. 5e), suggesting that DN2 progenitors that do not initiate Bcl11b-YFP 
expression may eventually lose the ability to activate this gene, although this possibility will 
require further investigation. Thus, while Notch signaling is not strictly necessary for Bcl11b 
transcriptional activation, it enhances the probabilistic rate of this event.
To assess how much Notch signaling is needed for Bcl11b activation, we compared the dose-
dependence of Bcl11b transcriptional activation on Notch signaling to the threshold for two 
other Notch-dependent responses, CD25 upregulation and restriction of non-T lineage 
development. Bcl11b-YFP− DN2a thymocytes were cultured in stromal cell-free conditions 
for 4 days with a range of doses of purified DL1-Fc (0–3.2 µg/ml) pre-bound to tissue 
culture plates34. DL1-Fc increased the fraction of DN2a cells becoming Bcl11b-YFP+ in a 
dose-dependent manner, but even a low dose of 0.2 µg/ml DL1-Fc enabled 50% the cells to 
turn on Bcl11b-YFP (Fig. 6a). Furthermore, increasing DL1-Fc concentrations enhanced the 
frequency of cells becoming Bcl11b-YFP+, but not the expression magnitudes of Bcl11b-
YFP in individual positive cells (Fig. 6; cf. bimodal response in Fig. 3b). Similar dose-
effects were observed upon pharmacological inhibition of Notch signaling by γ-secretase 
Inhibitor (Supplementary Fig. 5). Bcl11b-YFP could be fully activated in a major subset of 
DN2 cells by culture with DL1-Fc concentrations that did not sustain CD25 expression and 
did not suppress trans-differentiation to CD11c+ dendritic cells (Fig. 6b). Thus, Bcl11b 
activation requires a lower Notch signal compared to that required to regulate these other 
processes.
GATA-3 and TCF-1 control poising of Bcl11b for activation
The lower threshold for Notch signals to induce Bcl11b-YFP in DN2a thymocytes compared 
to ETPs suggested that another rate-limiting factor collaborates with Notch at DN2a stage to 
promote Bcl11b-YFP activation. Such factors could be activated by Notch signaling before 
or coincident with Bcl11b-YFP activation. Our transcriptome analyses showed few if any 
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new regulatory gene candidates to increase expression between Bcl11b-YFP− DN2 and 
Bcl11b-YFPlo DN2 besides Bcl11b itself (Fig. 2f; Supplementary Table 2b), although their 
activity or expression could be modulated post-transcriptionally. Therefore, we examined the 
roles of T cell transcription factors implicated previously by genetic evidence, namely 
GATA-3, TCF-1 (encoded by Tcf7) and Runx factors in a complex with CBFβ.
The T-cell specific factors GATA-3 and TCF-1 are activated by Notch signaling in the ETP 
stage, before Bcl11b activation35,36. To determine how and when these factors are needed 
for Bcl11b expression, we knocked down their expression in progenitors at different 
developmental stages using shRNA constructs, all validated in ETP and DN2 cells 
(Supplementary Fig. 6)17. Transduction of shRNA-Gata3 and shRNA-Tcf7 into ETP cells 
severely inhibited induction of Bcl11b-YFP in their progeny compared to cells transduced 
with a non-targeting control (shRandom)(Fig. 7a). GATA-3 and TCF-1 knockdown in 
descendants of DN1 cells mainly reduced the percentages of cells expressing Bcl11b-YFP, 
rather than the amount of Bcl11b-YFP expressed per cell (Fig.7a), like the effects of Notch 
inhibition. Production of CD25+ cells was also severely affected as expected15,16,19, 
consistent with an early developmental block. Although some of the cells did acquire a DN2 
phenotype, shRNA-Tcf7 further reduced the fraction of DN2 cells that activated Bcl11b-
YFP.
However, transduction of either shRNA-Gata3 or shRNA-Tcf7 into Bcl11b-YFP− DN2a 
cells had much less effect on Bcl11b-YFP activation than in ETPs (Fig. 7ab). Knockdown of 
GATA-3 from DN2a stage on had no detectable effects on Bcl11b-YFP activation. In DN2a 
cells, shRNA-Tcf7 effectively lowered a barrier to DC trans-differentiation (Supplementary 
Fig. 7a) but only mildly impeded Bcl11b-YFP induction compared to shRandom vector 
controls (Fig. 7ab). By DN2b stage, knock down of TCF-1 or GATA-3 had no effect on 
Bcl11b-YFP expression compared to random shRNA (Fig. 7b; Supplementary Fig. 8), 
consistent with reported RNA expression data37,38. Conversely, TCF-1 over-expression did 
not affect Bcl11b-YFP expression in either ETP or DN2 cells in our system (Supplementary 
Fig. 7b), suggesting that physiological levels of TCF-1 protein at ETP or DN2 stage are 
sufficient for maximum Bcl11b induction. These results indicate that GATA-3 and TCF-1 
together control entry of cells into a state poised for Bcl11b activation, but are largely 
dispensable for maintaining Bcl11b expression after commitment.
Runx1 controls Bcl11b expression amplitude
We next investigated how Bcl11b expression amplitude is controlled once activated. Because 
Runx-CBFβ transcriptional complexes are vital for development of T cells past the DN2 
stage14,39, Runx binding sites are prominent in the cis-regulatory regions of Bcl11b27, and 
germline CBFβ dose reduction severely impacts Bcl11b expression14, we tested whether 
Runx has a role in regulating Bcl11b transcription. We transduced Bcl11b-YFP− DN2 (Fig. 
8a) or Bcl11b-YFP+ (Fig. 8b) DN2 progenitors with either a Runx1 shRNA or a pan Runx 
dominant negative (Runx-DN) construct40 to inhibit Runx activity, or with full length Runx1 
cDNA to elevate Runx1 activity, and assessed the impacts on the magnitude of Bcl11b-YFP 
expression. shRNA-Runx1 down-shifted the whole distribution of Bcl11b-YFP expression 
compared to random shRNA or empty vector, whereas Runx1 over-expression up-shifted 
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Bcl11b-YFP expression, both during Bcl11b-YFP induction (Fig. 8a) and in cells that were 
already Bcl11b-YFP+ (Fig. 8b). Pan Runx-DN had a similar but milder effect than shRNA-
Runx1 in both cell types, suggesting that other Runx family members may only play minor 
roles. shRNA-Runx1 transduction also affected Bcl11b-YFP expression in descendants of 
both Bcl11b-YFP− DN2 (Fig. 8a) and Bcl11b-YFP+ DN2 cells (Fig. 8b) in the absence of 
Notch signaling (OP9, right panels), indicating that Runx supports the Notch-independent 
phase of Bcl11b expression as well.
To determine whether the roles established for Runx1, TCF-1 and GATA-3 during 
commitment persist, we examined their effects on Bcl11b expression in mature T cells. 
Knockdown of Runx1, but not TCF-1 or GATA-3, in activated, mature peripheral T cells 
reduced Bcl11b-YFP expression compared to control-transduced cells, both in CD8+ (Fig. 
8f,g) and in CD8− T cells (Supplementary Fig. 8). These data show that Runx1 plays a role 
distinct from that of Notch, GATA-3, or TCF-1, and controls the magnitude of Bcl11b 
expression even after T cells leave the thymus.
DISCUSSION
Bcl11b is induced sharply from a silent, repressed state to become fully expressed during 
commitment, between DN2a and DN2b stages. Although further modulated according to 
effector lineage and activation state3,4, Bcl11b is permanently expressed in all T cells, where 
it upholds T cell identity and suppresses NK fate3,5. Here we used a fluorescent Bcl11b 
reporter allele to show that the silence of Bcl11b in early ETPs is functionally different from 
its poised quiescence in early DN2a cells, before it activates dramatically during the T 
lineage commitment transition. We show that Notch signaling, GATA-3, TCF-1, and Runx1 
play distinct, stage-specific roles in controlling this watershed regulatory event. Notch-Delta 
signaling enhances the likelihood of switch-like Bcl11b activation from “poised” 
progenitors, but is dispensable to sustain Bcl11b expression once activated. GATA-3 and 
TCF-1 control entry into a state poised for Bcl11b activation, but are also unnecessary for 
stable expression of Bcl11b. Thus, Notch, GATA-3 and TCF-1 primarily act permissively. 
Notably, both GATA-3 and TCF-1 are activated by Notch signaling, suggesting a double 
feed-forward network circuit architecture for commitment control. In contrast, Runx1 
continuously affects Bcl11b expression magnitude with or without Notch signals, indicating 
an independent role in controlling Bcl11b expression after locus activation. Thus, multiple 
transcription factors, all necessary for T cell generation, collaborate asynchronously to 
establish cellular identity, and single-cell tracking clearly distinguishes the mechanisms they 
use to poise cells for commitment from those to execute and maintain lineage-specific gene 
expression.
Collaboration of multiple transcription factors is fundamental for establishing distinct cell 
type identities during multicellular organismal development41, and is also essential for 
artificial cell fate reprogramming42,43. In classical models of developmental gene regulation, 
it is often assumed that combinatorial function reflects synchronous transcription factor 
action at cis-regulatory DNA elements of target genes21,22. However, it is not clear whether 
all co-occupancy reflects synchronous transcription factor function. In a growing number of 
systems, lineage-specifying transcription factors are seen to act as `pioneers’, binding early 
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to physically open up developmental gene loci and enable subsequent binding of other 
factors23,24. These pioneer factors need not work coordinately with other factors, and may 
act transiently to generate lasting effects on gene expression23.
Our results suggest that GATA-3 and TCF-1, which turn on early in ETP cells, may act to 
“poise” Bcl11b for activation at a later stage. Once the Bcl11b locus is poised in Bcl11b-
YFP− DN2 cells, it then transitions to an active state in a Notch-dependent, IL-7-restrained 
manner, and then sustains expression through active regulation by Runx1. In this model, the 
combinatorial requirement for Notch, GATA-3 and TCF-1 makes Bcl11b induction possible 
only along a narrow range of developmental tracks: the T cell program and the ILC2 
program31. By the time cells reach Bcl11b-YFP− DN2 stage, they harbor a potential for 
activating Bcl11b that ETP cells lack, being “licensed” for Bcl11b activation. This licensing 
function could be highly related to “pioneering” or locus opening23,24; and is distinctive in 
that individual mediators of licensing can be removed later without affecting expression. An 
alternative interpretation is that GATA-3 and TCF-1 regulate Bcl11b indirectly through a 
later-acting intermediate factor, but the paucity of major regulatory changes concomitant 
with Bcl11b activation disfavors this possibility. When the Bcl11b locus is licensed for 
activation in “poised” cells (Bcl11b-YFP− DN2), activation still takes 2–4 days; these 
remarkably slow kinetics could involve a rate-limiting transition of the locus from an 
inactive to an active chromatin state, potentially through slow removal of repressive histone 
marks, DNA demethylation or translocation of the gene locus from the nuclear lamina25,27, 
an idea we are currently investigating. Once the Bcl11b locus is activated, its magnitude of 
expression is sustained by Runx factors. Although Runx factors are expressed from a much 
earlier stage, they may not be able to reach the relevant sites in the Bcl11b gene until after 
the “licensing” process is complete, possibly due to the initially repressed state of the 
Bcl11b locus27.
Unlike lessons gleaned from other well-studied genes, the mechanisms controlling the 
competence of Bcl11b to be turned on are thus distinct from those controlling its expression 
levels. This distinction is only revealed at the single-cell level. The hit-and-run licensing 
functions performed by Notch, GATA-3, and TCF-1 are separable from the continuous 
magnitude control by Runx1. We speculate that this separation is a key to potential 
developmental importance. The same factors that work together to create the T cell identity 
in progenitors end up working divergently in later effector T cell subsets. All of these cells 
need Bcl11b – but Notch signaling is shut down in most naive T cells; and TCF-1 and 
GATA-3 work together to control TH2 differentiation in CD4+ T cells, but the TCF-1/
GATA-3 ratio is tipped one way in CD8+ T effector cells and in the opposite way in 
regulatory T cells. We propose that these cells all continue to express Bcl11b because they 
express Runx1 or other Runx family members, and also share the developmental history of 
passing through the lineage-specific licensing process studied here. Making locus opening 
difficult but irreversible, using different factors to modulate levels, provides T cells with a 
guarantee that these factors can be re-used in multiple contexts. Given that transcription 
factors are typically re-deployed multiple times in multicellular organism development, we 
speculate that similar types of mechanisms might underlie regulation in other systems not 
yet studied in this way.
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ONLINE METHODS
Constructs
Gene targeting vectors for reporter insertion into Bcl11b were generated using a bacterial 
artificial chromosome (BAC) recombineering method44, involving two major steps. Firstly, a 
modified BAC containing the fluorescent reporter to be inserted into Bcl11b locus was 
generated. An internal ribosome entry site (IRES)-histone 2B-mCitrine yellow fluorescent 
protein (YFP) cassette was joined to a loxP-flanked kanamycin/neomycin (neo) drug 
selection cassette using fusion PCR, and inserted into a cloning vector (pGEM-T Easy, 
Promega, Madison, WI). Additional 5’ and 3’ homology arms to the 3’-untranslated region 
(UTR) of Bcl11b were then attached to this IRES-YFP-neo cassette through an additional 
round of fusion PCR. The resultant linear fragment was then inserted into a BAC containing 
the entire Bcl11b gene locus (RP24-282D6, from http://bacpac.chori.org), using a 
recombineering-competent bacterial strain (SW102,44). Correctly targeted BACs were then 
selected using kanamycin, and verified using PCR and pulse-field gel electrophoresis.
Secondly, targeting sequence from the reporter-modified BAC was retrieved. To generate a 
retrieval vector, homology regions for the ends of the short and long arms of the targeting 
vector were joined by fusion PCR, and ligated into a starting ampicillin-resistant vector 
(PL253,44) using the restriction enzymes NotI and SpeI (New England Biolabs, Ipswich, 
MA). Targeting sequence from the modified BAC was then retrieved into this vector using 
recombineering in SW102 cells, and resultant targeting vectors were selected using 
kanamycin and ampicillin. In performing this reaction, it was discovered that a 430bp 
sequence in the starting PL253 vector (between the restriction enzymes NotI and DraIII) 
recombined with the fluorescent protein cassette to generate an undesired side-product; this 
region was removed by excision using NotI and DraIII, followed by ligation using a bridging 
oligonucleotide containing these adjacent sites for these two restriction enzymes.
Banshee retroviral constructs were used as a starting point for constructing shRNA 
knockdown vectors17. To minimize interference in detection of Bcl11b-YFP fluorescence, 
we first made a mCherry-expressing shRNA retroviral backbone (Banshee-mCherry), by 
modifying the existing GFP-based shRNA knockdown vector (Banshee-GFP) using PCR 
cloning45. shRNA targeting sequences for Tcf7, Gata3, Runx1, or a random sequence, were 
then joined to a U6 promoter by oligonucleotide synthesis, and cloned into this Banshee-
mCherry backbone using the restriction enzymes BglII and HindIII. Hairpin sequences for 
these vectors are provided in Table S1.
Retroviral over-expression constructs were made from an mCherry-expressing backbone we 
previously generated (MSCV-IRES-mCherry)33, which was based on the NGFR derivative 
of the pMIGR1 retroviral vector kindly provided by L. Xu and W. Pear. Full length Runx1 
and the Runx dominant negative constructs were made in the laboratory by J. Telfer46, and 
were cloned upstream of the IRES sequence of this vector using the restriction enzymes 
BglII and EcoRI. The Histone-2B mCherry construct was inserted into the MSCV-NGFR 
vector using PCR cloning with the restriction enzymes BglII and EcoRI. All constructs were 
verified by sequencing. TCF-1 over-expression constructs and corresponding empty vector 
controls (MSCV-VEX-GFP) were kindly provided by A. Bhandoola.
Kueh et al. Page 10
Nat Immunol. Author manuscript; available in PMC 2017 January 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To generate non-fluorescent OP9-DL1 cells for live-cell imaging, we generated a pMX-
DL1-IRES-hCD8 retroviral construct for transfection into OP9 cells. This was achieved by 
PCR cloning of mouse Delta-like 1 from a cDNA clone (GenBank BC057400) into the 
pMX-IRES-hCD8 backbone (gift from N. Masuyama) using the restriction enzyme XhoI.
Generation of Bcl11b-YFP knock-in reporter mice
The IRES-YFP-neo cassette was knocked into the endogenous Bcl11b locus of V6.5 ES 
cells, through gene targeting vector transfection, followed by selection of individual 
neomycin/G418 resistant clones. Correctly targeted clones were identified by PCR and 
Southern Blot analysis (Fig. S2) and injected into C57/BL6 blastocyst embryos. Chimeric 
founder animals were then crossed to C57/BL6 mice, and offspring containing the knock-in 
reporter were then bred to homozygosity for this allele. To delete the loxP-flanked neomycin 
cassette from this reporter allele, Bcl11b animals were bred to the EIIA-Cre mouse strain 
[B6.FVB-Tg(EIIa-cre)C5379Lmgd/J, from Jackson labs], which expresses Cre recombinase 
in the germline. Offspring with a deleted neomycin cassette were identified using PCR, and 
then bred to homozygosity for this allele. For in vitro assays with bone marrow progenitors, 
Bcl11b-YFP mice were crossed to Bcl2 transgenic mice [B6.Cg-Tg(BCL2)25Wehi/J, from 
Jackson labs] to obtain offspring heterozygous for both alleles; the Bcl2 transgene was used 
to enhance cell survival in these assays. As V6.5 ES cells represent a hybrid between 
C57/BL6 and 129/Sv strains, we estimate that mice used for our experiments have a small (< 
12.5%) contribution from the 129/Sv genome. Both male and female animals were used as 
cell sources as we did not observe and sex-specific differences in our experimental results. 
Spleen and thymus were harvested from 4–6 week old mice, whereas bone marrow was 
harvested from 2–3 month old mice. All animals were bred and maintained in the Caltech 
Laboratory Animal Facility, under specific pathogen free conditions, and the protocol 
supporting animal breeding for this work was reviewed and approved by the Institute Animal 
Care and Use Committee of the California Institute of Technology.
Analysis of cell populations from thymus and spleen
To analyze Bcl11b-YFP expression in different cell populations, mice were sacrificed, 
thymuses or spleen were dissected, and single-cell suspensions were made. For later-stage 
precursors (ISP, DP, CD4, CD8 in the thymus), and for mature populations (CD8, CD4, 
CD4+CD25+, γδT, NKT, B, NK in the spleen), thymocyte or splenocyte cell suspensions 
were directly stained using antibodies to cell surface markers (Supplementary Table 4), and 
analyzed using a benchtop flow cytometer (MacsQuant, Miltenyi). For earlier stage 
precursors (ETP, DN2a, DN2b, DN3, DN4), mature cells were depleted from thymocyte 
suspensions by staining with biotinylated antibodies to mature cell markers and removal 
with streptavidin-conjugated magnetic beads before staining with fluorochrome-conjugated 
antibodies, as previously described11. Antibodies used for this analysis are all standard, 
commercially available monoclonal reagents with widely-established use to characterize 
immune cell populations in the mouse; details are given in Supplementary Table 4.
In vitro generation of T-cell progenitors from bone marrow
DN T-cell progenitors were obtained through ex vivo expansion of bone marrow stem and 
progenitor cells on OP9-DL1 co-cultures, following previously described procedures17,20,47 
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with minor modifications. Briefly, bone marrow was removed from the femur and tibia of 2–
3 month old Bcl11b-YFP mice. Suspensions of bone marrow cells were then prepared, 
stained for lineage markers using biotin-conjugated lineage antibodies (CD11b, CD11c, Gr1, 
TER-119, NK1.1, CD19, CD3), incubated with streptavidin-coated magnetic beads 
(Miltenyi Biotec), and passed through a magnetic column (Miltenyi Biotec). Lineage-
depleted (Lin-) cells were eluted and stored in liquid nitrogen in freezing media (50% FBS, 
40% αMEM, 10% DMSO) for future use. To facilitate their development into the DN2 
stage, frozen bone marrow cells were thawed and cultured on OP9-DL1 monolayers30 using 
standard culture medium [80% αMEM (Gibco), 20% HyClone Fetal Bovine Serum 
(Thermo Scientific), Pen Strep Glutamine (Gibco), 50 µM β-Mercaptoethanol (Sigma)] 
supplemented with 5 ng/ml IL-7 and 5 ng/ml Flt3L (Peprotech). To isolate T-cell 
progenitors, cultured cells were directly sorted after 7 days, or transduced with retroviral 
constructs 1 day prior to sorting. T-cell precursor subsets were sorted from the cultures using 
c-Kit, CD44, and CD25 to approximate as closely as possible ETP, DN2a, and DN2b 
phenotypes found in thymus. However, because the levels of c-Kit expression on these 
cultured T-cell precursors do not split populations as sharply as those found in vivo, we refer 
to these bone-marrow derived subsets as ETP, Bcl11b-YFPneg DN2, and Bcl11b-YFP+ DN2, 
respectively.
For retroviral transduction, cultured cells were disaggregated, filtered through a 40 µm nylon 
mesh, transferred onto Retronectin/DL1-coated virus bound plates prepared as described 
below, and cultured with standard media supplemented with 5 ng/ml IL-7, 5 ng/ml Flt3L, 
and 5 ng/ml SCF. For sorting, cells were stained with CD45, CD44, c-Kit, CD25, and a 
biotin-conjugated lineage cocktail (CD11b, CD11c, Gr1, TER-119, NK1.1, CD19, CD3), 
(for some experiments, see Supplementary Table 1); and were sorted for DN1 progenitors 
(Lin- CD45+c-KithiCD44hiCD25-) or DN2 progenitors (Lin-CD45+c-KithiCD44hiCD25+). 
DN2 progenitors were further subdivided according to their level of Bcl11b-YFP expression, 
as indicated (Figs. 2–7), and cells transduced with retrovirus were further isolated as 
mCherry+ cells (Figs. 6, 7).
For cell proliferation experiments (Fig. 3), sorted cells were further incubated with 5 µM of 
the CellTrace Violet cell proliferation dye (Invitrogen) at 37°C for 10 minutes prior to 
culture. The c-Myc retroviral construct was described previously33. The small molecule 
CDK4/6 inhibitor PD0332991 (Selleck Chemicals, Houston, TX) was added to culture 
medium at a final concentration of 2.1 µM in 0.02% DMSO.33.
In vitro developmental assays
Thymus or bone-marrow derived DN progenitors were seeded onto monolayers of OP9-GFP 
or OP9-DL1-GFP feeder cells30, and cultured in standard media supplemented with 5 ng/ml 
IL-7, 5 ng/ml FLt3L and 5 µm β-Mercaptoethanol, unless otherwise indicated. In alternate 
lineage potential assays (Fig. 2a and 2c), a fixed number of cells were deposited by the cell 
sorter into 96 well plates as indicated; for the other assays, cells were first sorted into tubes, 
and distributed manually afterwards. Cells were then cultured for the indicated amount of 
days, then harvested for flow cytometry. For analysis, cells were stained for CD45, CD25 
and other antibodies as indicated (Fig. 3, 6 and 7), or with CD11c, NK1.1 and DX5 for 
Kueh et al. Page 12
Nat Immunol. Author manuscript; available in PMC 2017 January 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
alternate lineage potential assays (Fig. 2). Stained cells were then analyzed using either the 
MacsQuant flow cytometer (Figs. 3, 5, and Supplementary Fig. 3), or the MacsQuant VYB 
flow cytometer (Figs. 6, 7, and Supplementary Fig. 5) for detection of mCherry fluorescence 
by 561nm laser excitation. For feeder-free cultures (Fig. 6), bone marrow-derived 
progenitors were cultured directly onto DL1 protein coated plates, prepared as a described 
above, with standard media supplemented with 5 ng/ml SCF, IL-7 and Flt3L, and 5 µM β-
mercaptoethanol.
For live imaging, in vitro developmental assays were modified in two ways: Firstly, non-
GFP expressing OP9 cells (either OP9 parental cells48, or OP9-DL1-hCD8 cells generated 
above) were used, to minimize interference in detection of the Bcl11b-YFP fluorescence 
signal. Secondly, we attached PDMS micromesh arrays (250 µm hole diameter, 
Microsurfaces, AU) to the surface of glass-bottomed 24 well plates (Mattek, Ashland, MA); 
these arrays contain small microwells that confine OP9 cells and T-cell progenitors to a 
single imaging field of view on 40× objective (see Supplementary Fig. 4). OP9 cells and 
sorted progenitors were then seeded into microwells at appropriate densities to enable cell 
tracking and prevent cell crowding (~8/well and 1/well, respectively).
To facilitate automated cell tracking in movies, cells were marked with constitutively 
expressed fluorescence markers in two ways: 1) infection with H2B-mCherry expressing 
retrovirus (FIg. 5A,B,D and E, and Fig. S4B). Here, sorted cells were then seeded onto 
virus-boated plates, and cultured in standard media with 5 ng/ml SCF, IL-7, and Flt3L. After 
8 hours of infection, cells were transferred onto OP9-DL1 monolayers in microwells, and 
then subject to timelapse live-cell imaging. 2) in situ staining with an fluorescence-
conjugated antibody to the pan-hematopoietic cell marker CD45. Following a previously 
described procedure49, 50 ng/ml of CD45-APC was added to the culture media for imaged 
cells. In separate experiments, we verified using flow cytometry that direct addition of this 
antibody to culture media did not affect the T-cell development at these stages (not shown).
Isolation, activation and transduction of peripheral T-cells
To purify peripheral T-cells from spleen, we incubated splenocytes with biotin-conjugated 
CD4 and CD8 antibodies, followed by streptavidin-coated magnetic beads (Miltenyi Biotec), 
and passed them through a magnetic column. Trapped CD4+ or CD8+ cells were then eluted, 
and activated by culture with anti-TCRβ (plate-immobilized, 1 µg/ml coating concentration) 
and anti-CD28 antibody (in solution, 1 µg/ml) for one day. After activation, cells were 
transferred onto retronectin and virus-coated plates for retroviral transduction. After three 
days, cells were resuspended, stained with a fluorescence-conjugated CD8 antibody, and 
then analyzed using flow cytometry. In these experiments, cells were cultured in lymphocyte 
media (RPMI medium supplemented with 10% fetal bovine serum, penicillin-streptomycin-
glutamine, nonessential amino acids, sodium pyruvate, and 2-mercaptoethanol) 
supplemented with 100 U/ml IL-2 (Peprotech). Figure 8f,g shows results for CD8+ cells 
while Supplementary Fig. 8b shows those for CD8− (CD4+) cells, because CD8 surface 
levels are more stable under these stimulation conditions.
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Statistical analysis of alternate lineage potential
In alternate lineage potential assays, wells seeded with low numbers of starting precursors 
(input numbers indicated on figure panels) were first scored for NK cell or DC development 
using flow cytometry, using the markers NK1.1-DX5 for NK cells and CD11c for DC (Fig. 
2a, bottom, and 2c). A model, logistic in log of starting cell number, was fit, and the 
probability of a positive well from 10 cells was taken as a measure of developmental 
potential. The effect of Bcl11b-YFP activation on developmental potential was estimated as 
the difference of these probabilities, and tested by comparing the difference to its standard 
error using a z-statistic.
Sample preparation for RNA-Seq
Total RNA was extracted from 1–2.5 million cells using Trizol (Invitrogen), and then 
subjected to two rounds of selection using Oligo-dT coupled magnetic beads (Dynabeads) 
according to the manufacturer’s protocol. About 50–100 ng polyadenylated mRNA per 
sample was obtained after double selection. RNA was fragmented to an average length of 
200 bp by Mg2+-catalyzed hydrolysis and then converted into cDNA by random priming. 
cDNA was then subjected to end repairing, adaptor ligation, size selection and one round of 
PCR amplification.
Analysis of RNA-Seq data
RNA-Seq data was analyzed with an established analysis pipeline consisting of the programs 
TopHat and Cufflinks50, and output data were further analyzed and visualized using 
MATLAB (Natick, MA). Briefly, reads from the sequencer were mapped onto the mm9 
reference genome using the Tophat. Gene expression values, in fragments per kilobase-
million (FPKM) were then obtained, and differential expression analysis with replicate 
biological data was then performed using the statistical model from the Cufflinks software.
For principal component analysis (PCA) of developmental trajectories (Fig. 2D), we first 
obtained the set of all differentially expressed genes across the ETP (DN1), DN2a and DN2b 
stages from our previous study25, using pairwise comparisons with a probabilistic cutoff of p 
< 0.002. FPKM values for these genes from both our past study and this current work were 
log-transformed and normalized across all conditions, with normalizations being performed 
separately for these two datasets to prevent non-developmental differences in gene 
expression from obscuring the PCA analysis. Projections and loadings along the first two 
principal components were then plotted (Fig. 2d).
For analysis of gene expression changes during Bcl11b activation, we either started with a 
list of genes that were differentially expressed upon Bcl11b activation (p < 0.005, between 
Bcl11b-YFP− and Bcl11b-YFP+ DN2 cells, Fig. 2e left and Supplementary Table 1), or with 
a manually selected list of regulatory genes known to be important for T-cell development 
(Fig. 2e right and Supplementary Table 2). Weakly expressed genes with a total count 
number < 5 were then excluded, and remaining genes were then subject to a hierarchical 
clustering using an un-weighted average distance metric. Computed clusters were then 
visualized using heat maps (Fig. 2e).
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Retroviral transduction and preparation of the DL1-coated plates
Viral particles were generated by transient co-transfection of the Phoenix-Eco packaging cell 
line with the retroviral construct and the pCL-Eco plasmid (Imgenex, San Diego, CA). Viral 
supernatants were harvested at two and three days after transfection, and immediately frozen 
at -80°C until use. For experiments involving retroviral transduction (Figs. 6–7), tissue 
culture plates (Costar, Corning) were incubated overnight with 33 µg/ml Retronectin 
(Clontech) and 2 µg/ml of DL1-ext-IgG protein, and then loaded with viral supernatant. 
Cells were then cultured directly on virus-bound plates under the conditions described 
below. For experiments involving culture of sorted progenitors on DL1-coated plates (Fig. 
6), tissue culture plates (Costar, Corning) were incubated overnight with 33 µg/ml 
Retronectin (Clontech) with different concentrations of the DL1-ext-IgG protein, as 
indicated.
Generation of OP9-DL1-hCD8 cell lines
OP9 cells48 were transduced with DL1-IRES-hCD8 retrovirus, and single hCD8- expressing 
cell clones were generated by sorting low, limiting numbers of hCD8+ cells onto 96 well 
plates. Individual clones of OP9-DL1-hCD8 infected cells were then assayed for their ability 
to support T-cell development and survival, and working clones were then expanded, frozen 
and used for subsequent experiments.
Live-cell imaging
Long-term timelapse imaging of cultured tells was performed using a previously described 
method with some modifications33. Briefly, imaging was performed on a motorized inverted 
fluorescence microscope (IX-81, Olympus) using a 40× 0.95 NA oil objective 
(Supplementary Fig. 4). The microscope was fitted with laser-based focus drift correction 
(ZDC, Olympus) to maintain a constant plane of imaging, and also fitted with a custom-built 
incubator to maintain a constant humidified environment at 37°C with 7% CO2. Images of 
cultured cells were acquired at fixed time intervals in the differential interference contrast 
(DIC), YFP, and mCherry or APC channels using image acquisition software (Metamorph, 
Molecular Devices). Shorter timelapse intervals (3 minutes) were for DIC image acquisition, 
whereas longer timelapse intervals (15 minutes) were used for acquisition of fluorescence 
images to minimize photo-toxicity. At each time interval, multiple microwells within the 
microwell array were visited using a motorized X-Y stage (ASI Scientific). To correct for 
uneven fluorescence illumination, tiled images of uniformly fluorescent beads (Tetraspeck 
beads, Invitrogen) were acquired in the same fluorescence channels, and processed to 
generate a correction matrix, as previously described33.
Image segmentation and analysis
Cells were segmented and tracked using custom image processing workflow implemented in 
MATLAB (Mathworks, Natick, MA), which we previously described in detail33. Briefly, 
this workflow involved the following steps: Firstly, images were corrected for uneven 
illumination correction and background-subtracted. A matrix for correcting uneven 
illumination was calculated from fluorescent bead images, and applied to the fluorescence 
images. Corrected images were then subtracted for background using a top-hat filter. 
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Secondly, cells were subject to automated segmentation. Images were smoothed using 
Gaussian filtering, run through a Laplacian filter to detect fluorescence object boundaries, 
and thresholded. Resultant closed object boundaries were then filled to generate solid 
segmented objects, and then subject to size and shape selection to identify cells. Thirdly, 
cells were tracked automatically. Objects from adjacent movie frames were matched using 
the Munkres assignment algorithm, using an objective function that incorporates differences 
in Euclidean distance, shape and object brightness. This automated tracking procedure 
generates many cell tracking, which are subsequently corrected using supervised methods, 
as described below. Fourthly, cell segmentation and tracking. Cells that were then 
automatically segmented and tracked were then subject to manual refinement to identify 
missed cells, split touching cells, and label cell division events. For one of the imaging data 
sets (data in Fig. 5a, b, d, e), we performed manual refinement on cell segmentation, but did 
not further refine automated cell tracking results, nor did we further utilize tracking 
information for subsequent analysis. To expedite these corrections, we developed a 
MATLAB graphical user interface that allows a user to review and edit objects and tracks 
from a timelapse movie. Image analysis code is available upon request from H.Y.K.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Bcl11b expression turns on in developing T-cell progenitors, and stays on throughout 
development and maturation
a) Flow cytometry analysis of Bcl11b-YFP levels in CD4, CD8 double negative (DN) 
thymocytes from single mice containing one, two or zero copies of the Bcl11b-YFP reporter 
allele, showing gates used for defining DN sub-populations (left), and Bcl11b-YFP level 
distributions for those populations (right). b) Mean Bcl11b-YFP levels from flow cytometry 
measurements in various T-cell populations from the thymus (left) or spleen (right) in 
Bcl11b-YFP reporter mice. Baseline levels in B cells and natural killer (NK) cells, both of 
which of which do not express Bcl11b, do not exceed 2.6 on this scale, similar to that of T 
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cells from control C57Bl/6 mice. c) Flow cytometry analysis of T-cell developmental 
progression and Bcl11b-YFP levels in sorted DN progenitors, cultured for three days on 
OP9-DL1 monolayers with 5 ng/ml IL-7 and Flt3L. Data are representative of two 
independent experiments (a,b), or three independent experiments (c).
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Figure 2. Bcl11b activation coincides with T-cell commitment
a) Analysis of dendritic cell (DC, CD11c+) or NK cell (NK1.1+ or DX5+, mixed antibodies) 
potential in thymic DN progenitors, assayed after 7–8 days on OP9 monolayers with IL-7 
and Flt3L. Wells were seeded with 300 cells (top), or the number indicated (bottom). Bars: 
fraction of wells with DC or NK progeny for the given number of seeded cells, and inferred 
lineage potential. Reduced NK and DC potentials between Bcl11b-YFP−DN2 and Bcl11b-
YFP+DN2 cells are significant (* - p = 0.01; ** - p = 0.002; z-test on logistic fit). b)-f) 
Transcriptomic analysis of bone-marrow DN2 progenitors using RNA-Seq. b) Sort strategy; 
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c) Analysis of developmental potential in bone-marrow DN progenitors by limiting dilution 
assays, showing less NK potential in Bcl11b-YFP+DN2 than in Bcl11b-YFP−DN2 (* - p = 
0.01; z-test on logistic fit). d) Principal component (PC) analysis (solid circles), showing 
projections along first two PC axes (top), and loadings of the top ten PC genes (bottom). DN 
populations from our previous study are shown25 (open circles). Arrow represents T-cell 
developmental trajectory. e) Hierarchical clustering analysis of the expression of genes 
differentially expressed in Bcl11b-YFPoff and Bcl11b-YFPon DN2 cells (left, q < 0.005), 
and selected T-cell regulatory genes (right). See Supplementary Tables 1 and 2 for FPKM 
values. Data in (a) represent 12, 11, and 12 replicates (for 2, 10 and 50 cells respectively) in 
one experiment, with similar results for three independent experiments. Data in (c) represent 
10 replicates in one experiment, with similar results for two independent experiments. 
Transcriptomic data (d,e) represent biological replicates from two experiments.
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Figure 3. Notch and IL-7 play opposing, stage-specific roles during early T-cell development
a) Flow cytometry analysis of Bcl11b-YFP expression for different BM-derived DN 
progenitor populations, after culture on OP9 or OP9-DL1 for the indicated number of days. 
Initial Bcl11b-YFP levels are shown (dotted lines). b) Flow cytometry of different BM-
derived DN progenitor populations, after culture under the indicated conditions for 4 days. 
Results are representative of two (IL-7 titration) or five (Notch withdrawal) independent 
experiments.
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Figure 4. Bcl11b activation is not coupled to Notch-dependent cell proliferation
a) Flow cytometry analysis of Bcl11b expression and cell division kinetics for Bcl11b-
YFP−DN2 progenitors stained with the cell division dye CellTrace Violet and cultured for 
four days. CellTrace Violet levels in starting cells are shown (dotted lines). The number of 
cell divisions is given by the log ratio of initial to final CellTrace Violet levels. b–c) Flow 
cytometry analysis of BM DN2 progenitors transduced with c-Myc, or treated with the 
cyclin-dependent kinase (CDK) 4/6 inhibitor PD0332991 (2.1 µM), and analyzed after four 
days. b) Fold increase in cell numbers under the indicated conditions. c) Analysis of Bcl11b-
YFP, CD25 and CD44 expression in the indicated cultured populations. EV – empty vector. 
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Data in (a) represent mean and S.D. of three replicates from one experiment, with similar 
results seen in independent experiments. Bars in (b) represent the mean of two replicates, 
each shown with circles; results in (b,c) are representative of two independent experiments.
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Figure 5. Notch signaling increases the probability of all-or-none Bcl11b activation
a)–d) Long-term timelapse imaging analysis of Bcl11b activation dynamics in single 
Bcl11b-YFP− DN2 progenitors on OP9 or OP9-DL1 monolayers. a) Time evolution of 
Bcl11b-YFP levels for a cohort of cells on OP9-DL1 (left, top) or OP9 (left, bottom) 
monolayers. Histograms (right) give binned cell data obtained at the indicated times (top). 
Data were shown starting at t~25 hrs onwards, reflecting the onset time for mCherry 
expression. Smooth lines indicate best fits to mixed Gaussian distributions. b) Single-cell 
Bcl11b-YFP time traces on OP9-DL1 (left) or OP9 (center) monolayers. Traces where 
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Bcl11b levels rise above background (gray shading) are indicated in red. Bars give fraction 
of lineages turning on Bcl11b, showing significant increase in Bcl11b-YFP+ lineages on 
OP9-DL1 (χ2=3.25, d.f. = 1; p=0.072). c) Bcl11b-YFP+ cells at 40 and 80 hours, showing 
significant increase in fraction of Bcl11b-YFP+ cells on OP9-DL1 (40 hrs: χ2=6.1, d.f. = 1; 
p=0.013; 80 hrs: χ2=26.7, d.f. = 1; p=2.4×10−7). d) Time evolution for Bcl11b-YFP+ cells, 
obtained from Gaussian fits in (a). Smooth curves represent fits to the logistic equation f = 
A/[1+e4ν(t−τ)/A]. Inset shows graphical depiction of parameters. Bars show initial Bcl11b-
YFP activation rate (v), and maximal fraction of Bcl11b-YFP+ cells (A) from logistic fits, 
with 95% confidence intervals indicated. Results in (a,c,d,e) were obtained from one 
experiment, and results in (b) were obtained from a separate experiment, where cells were 
tracked to 36 hours. Bar graph data in (b,c) were derived from the indicated number of cells 
(n). Similar results were observed in three independent experiments.
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Figure 6. Notch signaling increases Bcl11b activation probability in a dose-dependent manner
a–b) Flow cytometry analysis of BM Bcl11b-YFP−DN2 cells cultured on plates with 
surface-immobilized DL1 protein, and analyzed after 4 days. a) Levels of the dendritic cell 
marker CD11c (top), together with CD25 and Bcl11b-YFP levels (middle, bottom) in 
CD11c- cell populations. B) Percentage of CD11c+ dendritic cells (top), mean CD25 
expression levels (center), and Bcl11b-YFP+ percentages (bottom) as a function of DL1 
dosage. Curves represent best fit to hyperbolic function f(x) = x/(x + Ke) (bottom), or to a 
straight line (top, bottom), which was used due to lack of observable saturation in the 
concentration series. Ke = 0.28 µg/ml represents the DL1 dose required for half-maximal 
enhancement of Bcl11b activation. FSC - forward scatter. Results are representative of four 
independent experiments.
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Figure 7. Gata3 and Tcf7 control initial Bcl11b activation
a)–b) Flow cytometry analysis of BM DN progenitors transduced with shRNA to Gata3 
(shGata3) or Tcf7 (shTcf7), and cultured on OP9-DL1 monolayers with IL-7 and Flt3L for 
5–6 days. a) CD44, CD25 and Bcl11b-YFP levels for the indicated cell populations. Cells 
transduced with non-targeting shRNA sequence (shRandom) are shown with dotted lines. b) 
Fraction of Bcl11b-YFP+ cells under different conditions. Solid green circles represent data 
from an alternate Tcf7 targeting construct (see materials and methods). Gata3 and Tcf7 
knockdown significantly inhibits Bcl11b activation from ETPs, and in Bcl11b-YFP−DN2 
progenitors to a lesser extent (unequal variance t-test on perturbed versus control conditions, 
1-tailed; * p < 10−2; ** - p < 10−4), but shows little effect on Bcl11b expression after lineage 
commitment. Results in (a) are representative of two independent experiments, and data in 
(b) show means of the indicated number of replicates (n) from two independent experiments.
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Figure 8. Runx1 controls Bcl11b expression amplitude
a)–b) Flow cytometry analysis of BM DN progenitors transduced with Runx constructs, and 
cultured on OP9-DL1 or OP9 monolayers for 4 days. CD44, CD25 and Bcl11b-YFP levels 
are shown for initial Bcl11b-YFP−DN2 cells (a) or Bcl11b-YFP+DN2 cells (b). shRunx1– 
Runx1 shRNA targeting sequence; RunxDN – dominant negative Runx inhibitor; Runx1 – 
full length Runx1; shRandom – non-targeting shRNA sequence; empty – empty vector. In 
histograms, dotted lines indicate Bcl11b-YFP levels in unperturbed cells. c) Mean Bcl11b-
YFP levels under various Runx perturbation conditions. Altering Runx1 levels or activity 
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significantly alters Bcl1b-YFP levels (unequal variance t-test, 2-tailed; * p < 0.05; ** - p < 
0.01). d) Flow cytometry analysis of mature T cells activated with anti-TCRβ and anti-
CD28, transduced with the indicated shRNA constructs, and cultured for 3 days. Data shows 
CD8 T cells (see also Fig. S8). Cells transduced with random shRNA (black solid), and non-
fluorescent T cells (black dotted) are shown. Mean Bcl11b-YFP levels decrease significantly 
upon Runx1 knockdown (unequal variance t-test, 1-tailed; * p < 0.05). Results in (a,b) are 
representative of two (Runx, shRunx1) or three (RunxDN) independent experiments, and 
data in (c) represents data and means of the indicated number of replicates (n) from one 
experiment. Data in (d) represent means of two replicates from one experiment; results are 
representative of two independent experiments.
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